SavedAdd your journal

Journals / İstanbul Tıp Fakültesi Dergisi / 2017 / Cilt: 80 - Sayı: 3

Liver manifestations of Celiac disease

Çölyak hastalığının karaciğer tutulumları

Tolga DÜZENLİ
Alpaslan TANOĞLU
Pages
111–119
Publication Date
2017-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this regard, hepatic enzyme screening is recommended for patients diagnosed with CD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Celiac disease (CD) is characterized by persistent intolerance to wheat gluten and other gluten-like proteins found in cereals such as barley, rye, and oats.
📊
Key Findings & Data:Although CD accounts for 6%-9% of elevated hepatic enzymes, hypertransaminasemia can be seen in 40% of CD patients.
💡
Conclusion & Impact:In this regard, hepatic enzyme screening is recommended for patients diagnosed with CD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Çölyak hastalığı · Gluten · karaciğer

Abstract

Celiac disease (CD) is characterized by persistent intolerance to wheat gluten and other gluten-like proteins found in cereals such as barley, rye, and oats. It predominantly affects the proximal small intestine. Although CD is known as an enteropathy, an increasing number of extraintestinal manifestations have appeared in recent years. Although CD accounts for 6%-9% of elevated hepatic enzymes, hypertransaminasemia can be seen in 40% of CD patients. Although the only finding could be hypertransaminasemia, many liver diseases and CD co-morbidities have also been demonstrated. In this regard, hepatic enzyme screening is recommended for patients diagnosed with CD. CD-related liver disorders may be categorized into two main groups: cryptogenic hypertransaminase/celiac hepatitis and autoimmune liver diseases. In addition, many liver diseases can be associated with CD. In this article, we aimed to summarize the relation between CD and liver enzyme elevation and the approach to treating hypertransaminasemia in CD patients.

Özet

Çölyak hastalığı (ÇH) buğdaydaki glutene ve arpa, çavdar, yulaf gibi tahıllarda bulunan gluten benzeri diğer tahıl proteinlerine karşı kalıcı intoleransla karekterize, ağırlıklı olarak proksimal ince barsağı etkileyen bir hastalıktır. Bir enteropati olarak bilinmesine rağmen son yıllarda ortaya konulan ve belirginleşen gastrointestinal sistem dışı bulguları ile de kendini göstermektedir. ÇH, karaciğer enzim yüksekliklerinin %6-9’unu oluştururken, ÇH olanlarda ise karaciğer enzimlerindeki yükselme oranı %40’ lara varabilmektedir. ÇH’nda tek bulgu bazen karaciğer enzim yüksekliği olabildiği gibi; birçok karaciğer hastalığı ile ÇH birlikteliği de gösterilmiştir. Bu kapsamda ÇH tanısı konan hastalarda mutlaka karaciğer enzim taraması önerilmektedir. ÇH ilişkili karaciğer bozuklukları kriptojenik hipertransaminazemi ya da çölyak hepatiti ve otoimmün karaciğer hastalıkları olarak iki ana grupta değerlendirilebilir. Bunların yanında birçok karaciğer hastalığı ile de ÇH birlikteliği gösterilmiştir. Bu yazımızda ÇH ile karaciğer enzim yüksekliği ilişkisini inceleyerek, bu hastalıklara yaklaşımı özetlemeyi hedefledik.

🔖

Cite This Article

DÜZENLİ, T., TANOĞLU, A. (2017). Liver manifestations of Celiac disease. İstanbul Tıp Fakültesi Dergisi, Cilt: 80 - Sayı: 3, 111–119. https://ajindex.com/articles/92947

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013;62(1):43-52
  2. Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998;352(9121):26-9
  3. Sainsbury A, Sanders DS, Ford AC. Meta-analysis: coeliac disease and hypertransaminasaemia. Aliment Pharmacol Ther 2011;34(1):33-40
  4. Castillo NE, Vanga RR, Theethira TG, Rubio-Tapia A, Murray JA, Villafuerte J, et al. Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population. Am J Gastroenterol 2015;110(8):1216-22
  5. Hagander B, Berg NO, Brandt L, Nordén A, Sjölund K, Stenstam M. Hepatic injury in adult coeliac disease. Lancet 1977;2(8032):270-2
  6. Marciano F, Savoia M, Vajro P. Celiac disease-related hepatic injury: Insights into associated conditions and underlying pathomechanisms. Dig Liver Dis 2016;48(2):112-9
  7. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87
  8. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006;130(6):1886-900
  9. Korponay-Szabó IR, Halttunen T, Szalai Z, Laurila K, Király R, Kovács JB, et al. In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies. Gut 2004;53(5):641-8
  10. Vajro P, Maiuri L, Coletta S, Vincenzo A, De Auricchio S. Enhanced expression of intercellular adhesion molecule (ICAM) 1 and transferin receptor (TFR) in the hepatocytes of children with atypical celiac disease (CD) presenting as chronic hepatitis. J Pediatr Gastroenterol Nutr 1994;19:363
  11. Abenavoli L, Milic N, De Lorenzo A, Luzza F. A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. Endocrine 2013;43(1):65-7
  12. Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359(9301):150-7
  13. Kruse N, Neumann K, Schrage A, Derkow K, Schott E, Erben U, et al. Priming of CD4+ T cells by liver sinusoidal endothelial cells includes CD25 low fork head box protein 3-regulatory T cells suppressing autoimmune hepatitis. Hepatology 2009;50(6):1904-13
  14. Rubio-Tapia A, Murray JA. The liver in celiac